Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Bischoff

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Ovarian Research|July 31, 2023
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinomaPaul Jank, Jonas Leichsenring, Svenja Kolb, et al.
Human Pathology|September 24, 2023
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinomaSvenja Kolb, Inga Hoffmann, Nanna Monjé, et al.
EMBO Molecular Medicine|August 19, 2021
Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancerFlorian Uhlitz, Philip Bischoff, Stefan Peidli, et al.
Journal of Neuro-Oncology|December 4, 2024
TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progressionDavid Wasilewski, Tommaso Araceli, Philip Bischoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Ovarian Research|July 31, 2023
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinomaPaul Jank, Jonas Leichsenring, Svenja Kolb, et al.
Human Pathology|September 24, 2023
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinomaSvenja Kolb, Inga Hoffmann, Nanna Monjé, et al.
EMBO Molecular Medicine|August 19, 2021
Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancerFlorian Uhlitz, Philip Bischoff, Stefan Peidli, et al.
Journal of Neuro-Oncology|December 4, 2024
TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progressionDavid Wasilewski, Tommaso Araceli, Philip Bischoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.
Pageof 3